Leukemia and Lymphoma

Not all Guillain-Barré cases are associated with infection, and studies have suggested a link between the rare disorder and certain cancers, including lymphomas.

The supplemental new drug application (sNDA) filing includes data from 2 pivotal randomized phase 3 global studies, ALPINE and SEQUOIA, of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The target action date is October 22, 2022.

The mutation is more common than expected and associated with poor outcomes, according to researchers from St. Jude Children’s Research Hospital.

Primary central nervous system non-Hodgkin lymphomas are rare extranodal B-cell lymphomas with a poor prognosis and no standard treatment plan.

The new protocol for monitoring acute lymphoblastic leukemia (ALL) is simpler than current techniques and is at least as good as the current gold standard.

Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.

Researchers, as well as a patient who had chronic lymphocytic leukemia (CLL), hailed the findings as a cure, although more work needs to be done to see if the results persist in a larger group of patients.

On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.

Incyte has become the latest company to pull an FDA filing following Gilead and Secura Bio, which both voluntarily withdrew therapies that had been granted accelerated approval but hadn’t completed confirmatory studies for full approval.

A presentation at the 63rd American Society of Hematology (ASH) annual meeting explored the collection of real-world data.

Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.

The data published in Scientific Reports are the first to implicate a role for RASGRP4 mutations in B-cell malignancies.

While acute lymphoblastic leukemia (ALL) was still the primary cause of death, researchers saw a steady increase in 2-year survival from 27.8% to 54.8% even as patient age at the time of relapse after allogeneic hematopoietic stem cell transplantation (HCST) increased.

Graft-versus-host disease (GVHD) is common, yet it is poorly understood and its symptoms can be difficult to recognize.

The findings showing that older patients with chronic myeloid leukemia (CML) had poor adherence to tyrosine kinase inhibitors (TKIs) was presented last month during the American Society of Hematology Meeting & Exposition.

Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, discusses the National Comprehensive Cancer Network's (NCCN) preference for mRNA vaccines and how they work differently.

Articles on treating and protecting patients with blood cancers from COVID-19 and the positive results of zanubrutinib to treat leukemia and lymphoma were among the most read of the year.

Research using data from the ASH Research Collaborative COVID-19 Registry for Hematology identified risk factors for severe infection and mortality for patients with blood cancers who were infected with COVID-19.

There are 2 such vaccines now in use in the United States; the Pfizer-BioNTech vaccine is fully approved for the first 2 doses for those 16 and older, and the Moderna vaccine has an emergency use authorization for those 18 and older.

High-intensity interval training (HIIT) may maintain health, including immune cell function, for patients with treatment-naïve chronic lymphocytic leukemia (CLL).

Setting up a palliative care consultation program for patients with acute myeloid leukemia (AML) improved some aspects of care.

The researchers outlined potential treatment options for this patient population since the emergence and uptake of targeted treatments.

All-trans retinoic acid and arsenic trioxide used together can let children avoid treatment with convention chemotherapy, which has more adverse effects.

Although acute promyelocytic leukemia is highly treatable in early stages, the medication needed stop hematologic emergencies, all-trans retinoic acid, is often not available, a new study says.